Vancouver, BC — October 12, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) announces that new data on ANAVEX 2-73 will be presented in a poster session at Neuroscience 2012 in New Orleans. ANAVEX 2-73 is the company’s lead compound for Alzheimer’s disease currently in human clinical trials. Presentation details are as follows: Date: Wednesday, October…
New York, NY — September 21, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) today joins the Alzheimer’s Association® in recognizing September 21st as Alzheimer’s Action Day. September is World Alzheimer’s Month. In the United States alone, Alzheimer’s disease afflicts more than five million people and affects millions more husbands, wives, children, grandchildren, and…
Vancouver, BC — July 17, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced new and dramatic data concerning its Alzheimer’s disease treatment candidate ANAVEX 2-73 and leading Alzheimer’s treatments Aricept® (donepezil HCl) and Namenda® (memantine HCl).A clear synergic effect of ANAVEX 2-73 with Aricept® (donepezil HCl) has been demonstrated in a scientific…
Vancouver, BC — July 9, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease currently in human clinical trials, will be presented in a poster session at the 2012 Alzheimer’s Association International Conference (AAIC) in Vancouver, BC, Canada. The ANAVEX…
Vancouver, BC — June 26, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced the appointment of Robert Chisholm as Chief Financial Officer (“CFO”) of the company effective June 26, 2012. Mr. Chisholm will remain on the Anavex Board of Directors, on which he has served since May 2011. A veteran finance and…
Vancouver, BC — May 30, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on President Obama’s National Alzheimer’s Plan, which was unveiled earlier this month. It is part of the National Alzheimer’s Project Act (NAPA), which was signed into law in January 2011. NAPA is the first-ever national plan to address Alzheimer’s disease. …
Palo Alto, CA — February 14, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL)today announced that Dr. George F. Tidmarsh, MD, PhD, Executive Director, is scheduled to present a corporate update at the BIO CEO & Investor Conference in New York. Dr. Tidmarsh’s presentation will be webcast live and takes place on Tuesday, February…
Hoboken, NJ — November 14, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced the successful completion of its Phase 1 single ascending dose (SAD) clinical trial of ANAVEX 2-73, the company’s lead drug candidate for the treatment of Alzheimer’s Disease (AD). ANAVEX 2-73 is the first of a new class of oral…
Hoboken, NJ — October 12, 2011 — Anavex Life Sciences Corp., (“Anavex”) today announced the appointment of Dr. George Tidmarsh as director, and his engagement to act as an executive director. Dr. Tidmarsh is an executive-level physician/scientist and consultant who has founded and built several successful biotechnology companies. He has more than 20 years of…
HOBOKEN, NJ, September 16, 2011 – Anavex Life Sciences Corp. (“Anavex”) reports that Dr. Cameron Durrant has resigned as Director and Executive Chairman of the Board effective immediately. Anavex’s Board of Directors would like to thank Dr. Durrant for his contributions to the company and wish him well in his future endeavors. About Anavex Life…
